Sessions
Future-Proofing Cell Therapy Production
Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Add It Up: 3 Things to Consider for Capacity Expansion
Unlocking the Potential of Advanced Therapies Through Collaborations
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy
Future-Proofing Cell Therapy Production
This Session will:
- Define essential attributes to future-proof manufacturing.
- Discuss current industry strategies pursuing sustainable, flexible, and scalable processes.
- Explore the necessity and challenges of process standardization within the industry.
- Evaluate possibility of a platform that future-proofs both autologous and allogeneic therapies
Moderator:
Josh Ludwig, Global Director of Commercial Operations, ScaleReady
Panellists:
Mamta Kalra, Director CMC, Immatics
Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation, Vor Biopharma
Greta Garrido, Principal Scientist, NxACT, Nurix Therapeutics